Literature DB >> 16640573

The potential of azole antifungals against latent/persistent tuberculosis.

Zahoor Ahmad1, Sadhna Sharma, Gopal K Khuller.   

Abstract

The aim of the present study was to evaluate the chemotherapeutic potential of econazole against latent tuberculosis. The activity of econazole and clotrimazole was tested against the latent bacilli (Mycobacterium tuberculosis H(37)Rv) developed by nutrient starvation under in vitro conditions and by drugs under in vivo conditions. The latent bacteria developed under in vitro latent conditions were acid-fast negative, nonreplicating, resistant to conventional antitubercular drugs and showed low respiration rates. Econazole as well as clotrimazole were found to have strong antimycobacterial potential against latent Mycobacterium tuberculosis under in vitro conditions as seen by reductions in colony-forming units. Further, econazole prevented the formation of drug-induced latency and significantly reduced bacterial burden from lungs and spleens of latent tuberculosis-infected mice. We conclude that azole drugs bear significant therapeutic potential against latent tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16640573     DOI: 10.1111/j.1574-6968.2006.00224.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  26 in total

1.  Targeting tuberculosis through a small focused library of 1,2,3-triazoles.

Authors:  Guillermo R Labadie; Agustina de la Iglesia; Héctor R Morbidoni
Journal:  Mol Divers       Date:  2011-06-02       Impact factor: 2.943

Review 2.  The Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Hugues Ouellet; Jonathan B Johnston; Paul R Ortiz de Montellano
Journal:  Arch Biochem Biophys       Date:  2009-07-25       Impact factor: 4.013

3.  An enlarged, adaptable active site in CYP164 family P450 enzymes, the sole P450 in Mycobacterium leprae.

Authors:  Christopher R J Agnew; Andrew G S Warrilow; Nicholas M Burton; David C Lamb; Steven L Kelly; R Leo Brady
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

4.  DevS, a heme-containing two-component oxygen sensor of Mycobacterium tuberculosis.

Authors:  Alexandra Ioanoviciu; Erik T Yukl; Pierre Moënne-Loccoz; Paul R Ortiz de Montellano
Journal:  Biochemistry       Date:  2007-03-20       Impact factor: 3.162

Review 5.  Cholesterol catabolism as a therapeutic target in Mycobacterium tuberculosis.

Authors:  Hugues Ouellet; Jonathan B Johnston; Paul R Ortiz de Montellano
Journal:  Trends Microbiol       Date:  2011-09-15       Impact factor: 17.079

Review 6.  Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Paul R Ortiz de Montellano
Journal:  J Inorg Biochem       Date:  2018-01-12       Impact factor: 4.155

7.  Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1.

Authors:  Hugues Ouellet; Petrea M Kells; Paul R Ortiz de Montellano; Larissa M Podust
Journal:  Bioorg Med Chem Lett       Date:  2010-11-05       Impact factor: 2.823

8.  Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines.

Authors:  Larissa M Podust; Hugues Ouellet; Jens P von Kries; Paul R Ortiz de Montellano
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

9.  Identification and structural basis of the reaction catalyzed by CYP121, an essential cytochrome P450 in Mycobacterium tuberculosis.

Authors:  Pascal Belin; Marie Hélène Le Du; Alistair Fielding; Olivier Lequin; Mickaël Jacquet; Jean-Baptiste Charbonnier; Alain Lecoq; Robert Thai; Marie Courçon; Cédric Masson; Christophe Dugave; Roger Genet; Jean-Luc Pernodet; Muriel Gondry
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-22       Impact factor: 11.205

10.  Mycobacterium tuberculosis CYP130: crystal structure, biophysical characterization, and interactions with antifungal azole drugs.

Authors:  Hugues Ouellet; Larissa M Podust; Paul R Ortiz de Montellano
Journal:  J Biol Chem       Date:  2007-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.